Otsuka & Lundbeck v. Mylan & Viatris: ABILIFY MAINTENA Patent Infringement Dismissed Without Prejudice
Otsuka Pharmaceutical and H. Lundbeck brought an eight-patent infringement action against Mylan and Viatris in Delaware over generic versions of ABILIFY MAINTENA® aripiprazole extended-release injectable suspension. After 783 days of litigation, the case was dismissed without prejudice — suggesting a negotiated resolution while leaving the door open for future enforcement.
Eight-Patent ABILIFY MAINTENA Fight Ends Without Prejudice in Delaware
Filed on 8 April 2022 in the Delaware District Court before Judge Jennifer L. Hall, this Hatch-Waxman infringement action pitted branded pharmaceutical partners Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S against generic challengers Mylan NV, Mylan Pharmaceuticals, Inc., and Viatris, Inc. The plaintiffs asserted eight US patents covering aripiprazole extended-release injectable suspension formulations and methods of use — the active pharmaceutical and delivery technology underlying ABILIFY MAINTENA®, a long-acting injectable antipsychotic approved in 300 mg and 400 mg vial presentations.
The case closed on 30 May 2024 via a joint stipulation of dismissal without prejudice. Under the stipulated terms, all remaining claims and counterclaims were dismissed, the parties agreed to bear their own costs and attorneys’ fees, and the court expressly retained jurisdiction to adjudicate any disputes arising from settlement of the action. The without-prejudice designation means no final judgment on the merits was entered, and Otsuka and Lundbeck retain the right to refile infringement claims if circumstances warrant.
The 783-day duration and the explicit reservation of court jurisdiction over settlement disputes are consistent with a negotiated licensing or consent-decree resolution rather than a simple walk-away — a pattern common in branded-generic ANDA litigation where market exclusivity and launch timing are the primary commercial levers. The public record does not disclose whether a license was granted, a launch date was agreed, or other commercial terms were reached, so the ultimate competitive impact on the aripiprazole long-acting injectable market remains opaque.
Filing to Dismissed without Prejudice in 783 days
783 days in Delaware District Court — above the median for Hatch-Waxman ANDA disputes
Dismissed without prejudice: what the stipulated exit means for both parties
Stipulated dismissal without prejudice — no merits ruling
A voluntary dismissal without prejudice under a joint stipulation terminates the current action but does not adjudicate the validity or infringement of any asserted patent. The court entered no judgment on the merits. Otsuka and Lundbeck retain the full right to refile on any of the eight patents should a new trigger arise — for example, an imminent generic launch or a revised ANDA filing. The court’s express retention of jurisdiction over settlement-related disputes is a standard safeguard when a confidential agreement underlies the dismissal.
No merits adjudicationOtsuka and Lundbeck preserve all enforcement rights
Because the dismissal is without prejudice, none of the eight asserted patents has been found invalid, unenforceable, or not infringed by this proceeding. The patent estate covering ABILIFY MAINTENA — spanning formulation, dosage, and method-of-use claims — remains intact. If an undisclosed license was agreed, Otsuka and Lundbeck likely secured a controlled entry date, preserving near-term market exclusivity. The without-prejudice posture also gives them leverage against any other generic filers referencing the same ANDA.
Patent estate intactMylan and Viatris exit without invalidity finding — but on undisclosed terms
Mylan and Viatris also benefit from the absence of a merits ruling: no adverse judgment on infringement binds them. However, the without-prejudice framing means they cannot use this dismissal as a shield in future litigation. If the parties reached a license or settlement, the commercial terms — including any agreed launch date — remain confidential. A without-prejudice outcome gives Mylan/Viatris no IPR estoppel and no res judicata protection if Otsuka refiles before any agreed entry window opens.
No preclusion establishedLong-acting injectable antipsychotic market remains closely watched
ABILIFY MAINTENA competes in the high-value long-acting injectable antipsychotic segment. A without-prejudice resolution with eight patents still in force signals continued branded protection and suggests any generic entry timeline remains subject to negotiated constraints. Other ANDA filers targeting aripiprazole LAI formulations should treat the surviving patent estate as an active enforcement risk. The court’s retained jurisdiction clause further suggests the settlement agreement carries ongoing obligations that could affect future market dynamics.
Generic entry timing uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Otsuka Pharmaceutical Co., Ltd. | Company | Branded pharma and CNS specialist — co-holder of 8 aripiprazole injectable patents including US8030313B2Search in Eureka ↗ |
| Co-Plaintiff | H. Lundbeck, AS | Individual | Search in Eureka ↗ |
| Defendant | Mylan, NV | Company | Mylan NV / Mylan Pharmaceuticals and Viatris — generic drug manufacturer seeking ANDA approval for aripiprazole LAISearch in Eureka ↗ |
| Co-Defendant | Mylan Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Viatris, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | A. Sasha Hoyt | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Denise Main | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Erin M. Sommers | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | James B. Monroe | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jeanette M. Roorda | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Melanie Magdun | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Andrew Mark Moshos | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Bindu Ann George Palapura | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Brandon M. White | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Christine Dealy Haynes | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Christopher D. Jones | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | David Ellis Moore | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | David L. Anstaett | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Emily J. Greb | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Frederick L. Cottrell , III | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Ian Robert Liston | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jason James Rawnsley | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jonathan I Tietz | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Maria A. Stubbings | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Shannon M. Bloodworth | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Richards, Layton & Finger, PA | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Wilson Sonsini Goodrich & Rosati PC | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s phrasing — ‘dismissal, without prejudice, of all remaining claims and counterclaims’ — confirms that no issue was resolved on the merits. The phrase ‘all remaining’ suggests that some earlier claims or counterclaims may have been narrowed or resolved prior to dismissal, though the public record does not specify. The mutual cost-bearing provision is consistent with a negotiated resolution where neither side sought to characterise the outcome as a win. The court’s express retention of jurisdiction is the operative clause for future enforcement — it transforms the settlement into a judicially supervised agreement rather than a purely private contract.
US8030313B2 and 7 further patents — aripiprazole extended-release injectable suspension
The eight asserted patents collectively protect ABILIFY MAINTENA’s core technology: the formulation of aripiprazole as a stable aqueous extended-release suspension suitable for intramuscular depot injection, in 300 mg and 400 mg presentations. The portfolio spans multiple dimensions — crystalline particle suspension chemistry (US8030313B2, US8722679B2), dosing and titration methods (US8338427B2, US8399469B2), pharmacokinetic compositions (US10525057B2), and more recent continuation claims (US10980803B2, US11154553B1) that extend coverage into the 2030s. Application dates range from the mid-2000s to 2019, creating a staggered expiry profile that sustains enforcement windows well beyond the earliest filings.
Aripiprazole long-acting injectables occupy a high-value niche in CNS pharmacology, commanding premium pricing due to their adherence advantages in schizophrenia and bipolar disorder treatment. The breadth of this patent stack — eight patents across formulation, method-of-use, and continuation claims — is a deliberate defensive architecture designed to complicate generic entry even after the primary compound patents expire. For any manufacturer developing a competing aripiprazole depot formulation, the combination of formulation patents and method claims means that route-of-administration changes alone are unlikely to constitute a complete design-around.
Should you run an FTO analysis against the ABILIFY MAINTENA patent estate?
Any pharmaceutical company, CDMO, or generic manufacturer developing an aripiprazole extended-release injectable or a competing long-acting antipsychotic depot formulation should treat this eight-patent estate as a priority FTO target. The portfolio’s layered structure — spanning chemistry, method-of-use, and continuation claims — means a clearance opinion that addresses only granted claims may miss pending or recently issued continuations. The US11154553B1 patent, with application date in 2021, is particularly relevant for companies assessing near-term launch windows.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to run structured freedom-to-operate analysis across all eight ABILIFY MAINTENA patents simultaneously, mapping claim language against proposed formulation parameters and dosing protocols. Eureka surfaces family members, continuation applications, and cited prior art — giving in-house counsel and external advisers a comprehensive claim-by-claim clearance baseline before filing an ANDA or committing to formulation development capital.
Run a freedom-to-operate analysis on US8030313B2 to assess your product’s exposure
Run FTO in Eureka →Similar aripiprazole injectable and Hatch-Waxman ANDA cases in Delaware
Explore related Hatch-Waxman infringement actions involving aripiprazole formulations, long-acting injectables, and CNS depot drugs litigated in Delaware District Court.
What this case signals for the aripiprazole LAI and branded injectable IP landscape
Eight asserted patents, 783 days of litigation, and a without-prejudice exit: key strategic reads for pharma IP teams.
Without-prejudice dismissals in ANDA cases rarely mean unconditional exits
In Hatch-Waxman litigation, a stipulated dismissal without prejudice almost always reflects an underlying commercial agreement — typically a license with an agreed entry date. Generic entrants and brand competitors should not interpret this outcome as a cleared path to market. The eight-patent assertion and 783-day duration suggest significant negotiating leverage remained with Otsuka and Lundbeck throughout.
Retained court jurisdiction signals enforceable settlement obligations
The stipulation expressly reserves Delaware District Court jurisdiction over settlement disputes. This is a hallmark of a consent decree or structured license — not a simple walk-away. Brand and generic stakeholders in the aripiprazole LAI space should monitor docket activity in this case number for any future enforcement motions, which would surface if the agreed terms are breached.
Otsuka v Mylan — key questions answered
Eight patents were asserted: US8030313B2, US10525057B2, US8722679B2, US8338427B2, US8399469B2, US10980803B2, US7807680B2, and US11154553B1. All cover aspects of aripiprazole extended-release injectable suspension formulations and methods of use underlying ABILIFY MAINTENA® in 300 mg and 400 mg vial presentations.
The parties filed a joint stipulation of dismissal without prejudice, with each side bearing its own costs and attorneys’ fees. In Hatch-Waxman ANDA litigation, this outcome typically reflects a negotiated agreement — such as a license with a controlled entry date — rather than a simple walk-away. The public record does not disclose the specific commercial terms reached between Otsuka, Lundbeck, Mylan, and Viatris.
No. A dismissal without prejudice enters no judgment on the merits, meaning none of the eight asserted patents was found invalid, unenforceable, or not infringed. The full patent estate remains enforceable. Otsuka and Lundbeck retain the right to assert these patents against Mylan, Viatris, or other generic challengers in future proceedings.
The stipulation expressly reserves Delaware District Court jurisdiction to adjudicate disputes arising from the settlement. This provision is characteristic of a consent decree or structured license rather than an unconditional dismissal. It means that if either party breaches the underlying settlement agreement, the aggrieved party can seek enforcement directly in the same court without filing a new action.
The defendants are Mylan NV, Mylan Pharmaceuticals, Inc., and Viatris, Inc. The inclusion of Viatris reflects the 2020 merger of Mylan and Pfizer’s Upjohn division, which created Viatris. All three entities were named to ensure full liability coverage for the ANDA filing and any generic launch activities related to aripiprazole extended-release injectable suspension.
PatSnap Eureka searches patents and litigation data to answer instantly.